Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis

被引：1
|
作者：
Blauvelt, A. [1 ]
Langley, R. [2 ]
Leonardi, C. [3 ]
Gordon, K. [4 ]
Luger, T. [5 ]
Ohtsuki, M. [6 ]
Nickoloff, B. [7 ]
Kerr, L. [7 ]
Mallbris, L. [7 ]
Reich, K. [8 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Dalhousie Univ, Halifax, NS, Canada
[3] St Louis Univ, St Louis, MO 63103 USA
[4] Northwestern Univ, Feinberg Sch Med, St Louis, MO USA
[5] Univ Munster, Munster, Germany
[6] Jichi Med Univ, Shimotsuke, Japan
[7] Eli Lilly & Co, Indianapolis, IN 46285 USA
[8] Dermatologikum Hamburg & SCIderm Res Inst, Hamburg, Germany
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2016年 / 136卷 / 09期
关键词：
D O I：
10.1016/j.jid.2016.06.408
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
388
引用
收藏
页码：S227 / S227
页数：1
相关论文
共 50 条
  • [1] Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis
    Blauvelt, Andrew
    Langley, Richard
    Leonardi, Craig
    Gordon, Kenneth
    Luger, Thomas
    Ohtsuki, Mamitoro
    Nickoloff, Brian
    Kerr, Lisa
    Cameron, Gregory
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB258 - AB258
  • [2] Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis
    Blauvelt, A.
    Langley, R. G.
    Leonardi, C.
    Gordon, K.
    Luger, T.
    Ohtsuki, M.
    Nickoloff, B. J.
    Kerr, L. F.
    Cameron, G. S.
    Mallbris, L.
    Muram, T.
    Konrad, R.
    Komocsar, W.
    Leutz, A.
    Reich, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 107 - 108
  • [3] Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in subjects with moderate to severe plaque psoriasis
    Reich, Kristian
    Blauvelt, Andrew
    Armstrong, April
    Fox, Todd
    Huang, Jiaqing
    Bruin, Gerard
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S15 - S15
  • [4] IXEKIZUMAB Anti-IL-17A monoclonal antibody Treatment of psoriasis
    Haddley, K.
    DRUGS OF THE FUTURE, 2015, 40 (07) : 421 - 431
  • [5] Secukinumab, a novel anti-interleukin-17A antibody, exhibits low immunogenicity during long-term treatment in subjects with psoriasis
    Reich, K.
    Blauvelt, A.
    Armstrong, A.
    Fox, T.
    Huang, J.
    Lloyd, P.
    Bruin, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (06) : E166 - E167
  • [6] Ixekizumab: an anti-IL-17A monoclonal antibody for the treatment of psoriatic arthritis
    Toussirot, Eric
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (01) : 101 - 107
  • [7] Immunogenicity of the anti-IL-17A antibody secukinumab in healthy subjects and patients
    Klein, U.
    Liang, E.
    Vogel, B.
    Kolbinger, F.
    Bruin, G.
    Lloyd, P.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 : S172 - S172
  • [8] Decreased expression of IL-17 pathway genes in blood in patients with plaque psoriasis treated with the anti-IL-17A monoclonal antibody, ixekizumab
    Krueger, J. G.
    Dow, E. R.
    Nantz, E.
    Komocsar, W. J.
    Banerjee, P.
    Leonardi, C.
    Cameron, G. S.
    Banerjee, S.
    Hoffman, R. W.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 : S18 - S18
  • [9] Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis
    Blauvelt, Andrew
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (02) : 255 - 263
  • [10] Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis
    Fargnoli, Maria Concetta
    CASE REPORTS IN DERMATOLOGY, 2019, 11 : 1 - 3
12345